BioNTech Se (NASDAQ: BNTX)
Key Data Points
BioNTech Se Return vs. S&P
1 Year | 5 Year | 5 Year Annualized | Since IPO |
---|
BioNTech Se Company Info
BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.
News & Analysis
BioNTech Surpasses Q4 Revenue Estimates
BioNTech SE exceeded earnings expectations with strong oncology pipeline development, despite reduced vaccine revenue.
3 Dirt-Cheap Stocks to Buy in a Market That's Priced for Perfection
3 No-Brainer Biotech Stocks to Buy With $200 Right Now
2 Healthcare Stocks to Buy Hand Over Fist and 1 to Avoid
Is BioNTech Stock a Buy Now?
Or is it too late to get in on the company after its coronavirus-related success?
Why BioNTech Stock Was Sinking Today
While the waning of the COVID pandemic is a positive development for the world, it's left the German biotech struggling.
Why Shares of BioNTech Rose Friday
The company released positive trial data for a non-small cell lung cancer therapy.
2 Undervalued Stocks to Buy for Potentially Massive Gains in the Next 10 Years
Both are experiencing a bit of a hangover from declining COVID-19-related sales.
Financial Health
General
Q4 2024 | YoY Change |
---|
Revenue Growth Rate
Earnings Per Share Growth Rate
Assets
Q4 2024 | YoY Change |
---|
Liabilities
Q4 2024 | YoY Change |
---|
Ratios
Q4 2024 | YoY Change |
---|
Cash Flow
Q4 2024 | YoY Change |
---|
Valuation
Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | YoY Change |
---|
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.